Evercore ISI initiated coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research report released on Monday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $25.00 target price on the stock.
Shares of MIRM stock opened at $13.45 on Monday. Mirum Pharmaceuticals has a one year low of $12.05 and a one year high of $15.50.
In other Mirum Pharmaceuticals news, major shareholder Holdings A/S Novo bought 575,000 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The shares were purchased at an average cost of $15.00 per share, with a total value of $8,625,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Patrick J. Heron bought 450,000 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $6,750,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 1,357,000 shares of company stock worth $20,355,000.
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Recommended Story: What is Blockchain?
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.